Abstract: Objective To evaluate the efficacy and prognostic value of maximum standardized uptake (SUV_max) of ¹⁸F-flurodeoxyglucose positron emission tomography/computed tomography(¹⁸F-FDG PET/CT) in B-cell non-Hodgkin's lymphoma (NHL). Methods A total of 47 patients with B-cell non-Hodgkin's lymphoma treated in Beijing Shijitan Hospital, Capital Medical University from August 2016 to September 2019 were retrospectively analyzed. The correlation between baseline SUV_max and clinicopathological factors, laboratory indexes was evaluated. Receiver operating characteristic (ROC) curve analysis was used to determine the optimal point of SUV_max for disease progression, and the prognostic value of SUV_max was analyzed. Results ①There were significant differences between the baseline SUV_max and lactic dehydrogenase(LDH) level, progression status within 1 year, pathological types, respectively; ②Take the 1-year progression rate as the cut-off point, the optimal point of SUV_max was 14.4, the median progression-free survival (PFS) and overall survival (OS) of patients with SUV_max＜14.4 were significantly higher than those with SUV_max≥14.4,P<0.05; ③Take the disease progression as the cut-off point, the optimal pointof SUV_max was 16.7, the median PFS of patients with SUV_max＜16.7 were significantly higher than those with SUV_max≥16.7,P=0.025. Conclusion Baseline SUV_max of patients with B-cell lymphoma is closely related to the curative effect and survival, which has great clinical value.

Key words: B-cell non-Hodgkin's lymphoma, ¹⁸F-flurodeoxyglucose positron emission tomography/computed tomography(¹⁸F-FDG PET/CT), maximum standardized uptake, progression-free survival, overall survival